Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study.

Autor:	Baricich A; Physical and Rehabilitation Medicine, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.; Physical and Rehabilitation Medicine, 'Ospedale Maggiore della Carità' University Hospital, Novara, Italy., Battaglia M; Physical and Rehabilitation Medicine, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.; Physical and Rehabilitation Medicine, 'Ospedale Maggiore della Carità' University Hospital, Novara, Italy., Cuneo D; Physical and Rehabilitation Medicine, A.S.L. Vercelli, Vercelli, Italy., Cosenza L; Rehabilitation Unit, Department of Rehabilitation, 'Santi Antonio e Biagio e Cesare Arrigo' National Hospital, Alessandria, Italy., Millevolte M; Neurorehabilitation Clinic, Department Neurological Sciences, University Hospital of Ancona, Ancona, Italy., Cosma M; Neuroscience and Rehabilitation Department, Ferrara University Hospital, Ferrara, Italy., Filippetti M; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy., Dalise S; Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Azzollini V; Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Chisari C; Neurorehabilitation Section, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Spina S; Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia, Foggia, Italy., Cinone N; Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia, Foggia, Italy., Scotti L; Department of Translational Medicine, Unit of Medical Statistics, Università del Piemonte Orientale, Novara, Italy., Invernizzi M; Physical and Rehabilitation Medicine, Department of Health Sciences, Università del Piemonte Orientale, Novara, Italy.; Dipartimento Attività Integrate Ricerca e Innovazione (DAIRI), Translational Medicine, 'Santi Antonio e Biagio e Cesare Arrigo' National Hospital, Alessandria, Italy., Paolucci S; IRCCS Fondazione Santa Lucia, Rome, Italy., Picelli A; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy., Santamato A; Spasticity and Movement Disorder Unit, Physical Medicine and Rehabilitation, Policlinico Riuniti, University of Foggia, Foggia, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in neurology [Front Neurol] 2023 Apr 06; Vol. 14, pp. 1133390. Date of Electronic Publication: 2023 Apr 06 (Print Publication: 2023).
DOI:	10.3389/fneur.2023.1133390
Abstrakt:	Botulinum toxin type A (BoNT-A) is the treatment of choice for focal spasticity, with a concomitant effect on pain reduction and improvement of quality of life (QoL). Current evidence of its efficacy is based mainly on post stroke spasticity. This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect in improving all the outcome variables, with different effect persistence over time in relation to the diagnosis and the number of treated sites. Our results support BoNT-A as a modifier of the disability condition and suggest its implementation in the treatment of NSS, delivering a possible starting point to generate diagnosis-specific follow-up programs. Clinical Trial Identifier: NCT04673240. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Baricich, Battaglia, Cuneo, Cosenza, Millevolte, Cosma, Filippetti, Dalise, Azzollini, Chisari, Spina, Cinone, Scotti, Invernizzi, Paolucci, Picelli and Santamato.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu